Cargando…
Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade
Objective. Acquired chemoresistance is a major obstacle in the clinical management of ovarian cancer. Therefore, searching for alternative therapeutic modalities is urgently needed. Bitter melon (Momordica charantia) is a traditional dietary fruit, but its extract also shows potential medicinal valu...
Autores principales: | Yung, Mingo M. H., Ross, Fiona A., Hardie, D. Grahame, Leung, Thomas H. Y., Zhan, Jinbiao, Ngan, Hextan Y. S., Chan, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689379/ https://www.ncbi.nlm.nih.gov/pubmed/26487740 http://dx.doi.org/10.1177/1534735415611747 |
Ejemplares similares
-
Effects of Momordica charantia (Bitter Melon) on Ischemic Diabetic Myocardium
por: Czompa, Attila, et al.
Publicado: (2017) -
A case of atrial fibrillation due to Momordica charantia (bitter melon)
por: Erden, Ismail, et al.
Publicado: (2010) -
Diverse roles of bitter melon (Momordica charantia) in prevention of oral cancer
por: Sur, Subhayan, et al.
Publicado: (2021) -
Characterization of a Soluble Phosphatidic Acid Phosphatase in Bitter Melon (Momordica charantia)
por: Cao, Heping, et al.
Publicado: (2014) -
Identification and Characterization of Phenylpropanoid Biosynthetic Genes and Their Accumulation in Bitter Melon (Momordica charantia)
por: Cuong, Do Manh, et al.
Publicado: (2018)